Inflammatory Bowel Disease
Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
Lycera, a biopharmaceutical company and University of Michigan spinoff, plans to partner and collaborate with U-M faculty and students with a move to UM’s North Campus Research Complex.
Kalamazoo-based NephRx Corp. has been issued of a United States patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.
The Plymouth-based biopharmaceutical developer Lycera Corp. Thursday announced an exclusive research collaboration with pharma giant Merck to develop drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis